BACKGROUND: The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-M  llerian hormone ( @entity248 ) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated @entity248 and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in @entity0 @entity1 . MATERIALS AND METHODS: To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms " @entity2588 / @entity43 ," "anti-Mullerian hormone/blood," and " @entity0 /drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline @entity248 and age model. RESULTS: The meta-analysis of data pooled from the selected studies showed that both age and serum @entity248 are reliable predictors of post-treatment ovarian activity in @entity0 @entity1 . Importantly, ROC/AUC analysis indicated @entity248 was a more reliable predictor of post-treatment ovarian activity in @entity1 aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602-0.904) compared with those older than 40 years (0.678; 95% CI: 0.491-0.866). We generated a nomogram describing the correlations among age, pretreatment @entity248 serum levels, and ovarian activity at 1 year from the end of chemotherapy. CONCLUSION: After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal @entity1 requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures. IMPLICATIONS FOR PRACTICE: In general, a nomogram helps clinicians better visualize a specific risk for a single @entity1 . In premenopausal @entity1 affected by early @entity0 who need adjuvant cytotoxic regimens, the proposed nomogram-based on the assessment of pretreatment age and anti-M  llerian hormone serum levels-can assess the personal probability of maintaining ovarian activity at 1 year from the end of chemotherapy. The ongoing validation process is also evaluating other key factors contributing to post-treatment ovarian activity (i.e., type of cytotoxic regimen) and will confirm the nomogram's reliability and clinical utility.

Predicting Ovarian Activity in XXXX Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['chemically induced," "ovarian reserve'] @entity248 :: ('268', 'Gene') :: ['AMH'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast neoplasms'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']
@entity1 :: (9606,Species) :: ['Women']
